We use an innovative chip-based drug screening technology to find a small new molecule, Cyn-1324 that has been experimentally confirmed to have low toxicity and high efficacy for treating with immuno-suppressive diseases such as asthma. The application of IND (investigational new drug) is under preparation. This drug screening method therefore has been identified as for its usefulness and afterward valuable new drug commercialization.

We created an innovative chip-based drug screening technology (two ROC patents granted; one US patent in pending) to find new drug(s) for treating with disease(s). For the first time, we immobilize a T-cell membrane receptor (CD28) on the chip under the influence of an external electric field that can perform an efficient “array” assemble of protein on chip.  Consequently, a small molecule (an inhibitor, Cyn-1324; ROC, USA and PROC patents granted) was found that can block the binding between CD28 (T-cell) and CD80 (APC cell) efficiently. Up to now, an IND application (apply for Phase I clinical trial) is under preparation. This chip-based drug screening method is therefore considered as for its usefulness.   Many disease-related new drug finding(s) can be done and continued to be developed as for its final goal-commercialization. Both market and industrialization are huge and practical.  
The reasons for investing this drug screening technology and afterward new drug commercialization (for example, Cyn-1324 is selected for treating with its first indication: asthma) are: (a) Opportunity. There have many side-effects coming from current popular anti-asthma drugs. For example, the current drug, Singulair®, US/FDA warns that the side-effects such as irritability, violence, depression, insomnia, prickliness, desolation and suicidal behavior, etc. happen frequently from the asthma patients. However, Cyn-1324 has less such side-effects and therefore is “highly demanding”. (b) Value. The current asthma patients must to have this new drug since less toxicity and cost-effectiveness. (c) Why me? Cyn-1324 is cost-effective, less side-effect and high efficacy. (d) Market. Both current market of Singulair and Xolair are US5.9 and 1.5 billions, respectively. We predict that Cyn-1324 may conquer about 20% market with licensing fee about NT4.5 billions; (e) Uniqueness. Cyn-1324 is currently only drug to block the asthma symptom pathway (Th-2 pathway) at its early stage. (f) Business model. The licensing will be conducted after or during the Phase I and II. The first income with about US0.1 to 0.15 billions may be accepted. The continued new drug findings will be proceeded under our efficient chip-based drug screening technology.

本篩選技術已包含四個重大疾病領域的新藥篩選與開發: 1. 抗過敏 (如本申請案的抗氣喘新藥，Cyn-1324); 2. 癌症; 3. 糖尿病; 4.骨質疏鬆。